Rheumatoid arthritis and psoriatic arthritis are the only indications that have received regulatory approval. Arava was developed by Sanofi Aventis and approved by the U.S. Food and Drug Administration in 1998. Clinical studies regarding the following diseases have been conducted: There has been reports on potential re-purposing of<unk>  for treatment of solid tumors with tumor suppressor, PTEN, loss. In PTEN negative tumors,<unk>  causes synthetic lethality potentially due to increased demand on pyrimidines in these faster growing cells. * Polyoma BK virus nephropathy * Kimura's disease * Systemic lupus erythematosus * Felty's syndrome * Takayasu arteritis * Granulomatosis with polyangiitis * Ankylosing spondylitis * Crohn's disease * Sarcoidosis * Uveitis * Still's disease * Prostate cancer * Pemphigoid * Prevention of organ transplant rejection
Leflunomide
Tofacitinib
Etanercept
Teriflunomide
Belatacept
Belimumab
Adalimumab
Anakinra